SALT LAKE CITY, May 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 million reported in the third fiscal quarter of 2011. Earnings per diluted share were $0.34, an increase of 10 percent over the same period of the prior year.
